Shares of Recro Pharma (NASDAQ:REPH) fell 7.4% in pre-market trading after the company reported Q1 results.
Earnings per share were down 230.00% year over year to ($0.33), which missed the estimate of ($0.03).
Revenue of $21,777,000 lower by 13.12% from the same period last year, which beat the estimate of $19,450,000.
Recro Pharma hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Recent Stock Performance
Company's 52-week high was at $19.21
Company's 52-week low was at $6.10
Price action over last quarter: down 18.09%
Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products. Its product portfolio includes Ritalin LA; Focalin XR; Verelan PM, SR and Verapamil PM; Verapamil SR and Zohydro ER.